SMA Combination denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sma combination are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for Combination SMA Therapy

Prior authorization (PA) for SMA combination therapy is one of the most common administrative barriers patients face. BCBS applies PA requirements to disease-modifying SMA agents individually, and when two agents are prescribed together, each may require its own separate authorization. A PA denial — as opposed to a PA requirement — means the authorization request was submitted but did not meet the plan's criteria as documented in the submission.

## Why This Denial Is Appealable

A prior-authorization denial is an adverse benefit determination and carries full appeal rights under federal and state law. The most common reason PA requests fail is incomplete documentation: the submission did not include all the clinical evidence the plan's criteria require. A thorough appeal that directly addresses each PA criterion with corresponding chart evidence succeeds at a higher rate than the initial submission in most specialty-drug categories.

## Federal Appeal Framework

• Urgent reconsideration / peer-to-peer review: Before filing a formal appeal, ask for a peer-to-peer call between the treating neurologist and the BCBS medical director. Many PA denials are reversed at this step when the prescriber explains the full clinical picture directly.
• Internal appeal (Level 1): Submit a formal written appeal with complete documentation. BCBS must respond within plan-mandated timeframes (standard: typically 30 days; urgent: typically 72 hours or less).
• External review (ACA §2719): If the internal appeal is denied, request independent external review. The federal window is generally four months from the adverse determination letter; confirm your exact deadline.
• Expedited external review: Available simultaneously with expedited internal appeal when delay poses serious health risk.
• ERISA §503: Employer self-funded plans must provide a full-and-fair review including all evidence relied upon by the plan.

## Documentation to Gather

1. Denial letter with specific criteria cited: Request the complete PA denial letter and the specific criteria the plan applied. You cannot appeal efficiently without knowing exactly what was found insufficient. 2. Confirmed diagnosis and genetic report: SMA type, SMN copy number, and any additional genetic findings relevant to treatment selection. 3. Functional baseline and trajectory: Current and historical motor function assessments, respiratory status, and swallowing/feeding status from the chart. 4. Prior therapy documentation: All prior SMA treatments with dates, duration, dose (as prescribed by the treating physician), and documented outcomes. 5. Prescriber medical-necessity letter: Detailed, signed letter from the neuromuscular specialist addressing each PA criterion point-by-point with specific chart references. 6. FDA labeling for each agent: Confirm the requested use matches the approved indication.

## Criteria-Mapping Structure

Obtain BCBS's PA criteria for each SMA agent from their provider portal or by formal request. For each criterion:

| PA Criterion | Chart Evidence Submitted | Document/Date | |---|---|---| | Diagnosis confirmation | Genetic test + neurology note | ___ | | SMA type and severity | Neurology assessment | ___ | | Age / weight eligibility (per FDA label) | Chart demographics | ___ | | Prior therapy requirement (if any) | Treatment history records | ___ | | Prescribing specialist requirement | Neurologist credentials | ___ | | Current functional status | Validated scale assessment | ___ |

Submit this table with your appeal. Unanswered criteria are the primary reason appeals are denied on the second round.